目的:报告临床使用情况,不良事件,在狗的开放性伤口管理或封闭式伤口应用中,在30%泊洛沙姆407(阿米卡星-P407)中使用阿米卡星后的结果。
方法:29只客户拥有的狗。
方法:对一家医院2017年1月至2023年8月的医疗记录进行了审查,检查了在开放性或封闭式伤口应用中接受阿米卡星-P407的狗。审查的信息包括标志,伤口和/或手术部位感染(SSI)的性质,细菌培养物,阿米卡星剂量,凝胶体积,给药途径,估计的伤口表面积,生物化学参数,尿液铸型,伤口进展,和一般临床结果。
结果:在开放性伤口护理中应用了阿米卡星-P407(10只狗),通过注射(5只狗),并且在伤口闭合时(13只狗),并用于开放和封闭伤口管理(1只狗)。在30个站点中,有18个与SSIs相关。在30个应用前培养物中的21个中发现了多药耐药性。阿米卡星剂量中位数为14.5mg/kg(范围,3至59.5mg/kg),中位总体积为5.0mL(范围,1至12mL),和中值组织表面积为6.6cm2(范围,1.6至36cm2),对于62.5mg/cm2的局部伤口剂量(范围,6.9至214.3mg/cm2)。在任何伤口或狗中没有注意到短期不利的局部或全身作用。在19个封闭地点中的17个没有看到开裂。
结论:本病例系列的结果表明,阿米卡星-P407可以以多种方式应用,而无不良反应。阿米卡星-P407可以在开放性伤口管理中或在感染伤口和SSI的封闭环境中考虑。
OBJECTIVE: To report the clinical use, adverse events, and outcomes after using amikacin in 30% poloxamer 407 (amikacin-P407) during open wound management or in a closed wound application in dogs.
METHODS: 29 client-owned dogs.
METHODS: Medical records from January 2017 to August 2023 from a single hospital were reviewed for dogs that received amikacin-P407 in an open or closed wound application. Information reviewed included signalment, nature of wound and/or surgical site infection (SSI), bacterial cultures, amikacin dose, gel volume, route of administration, estimated wound surface area, biochemistry parameters, urine casts, wound progression, and general clinical outcome.
RESULTS: Amikacin-P407 was applied during open wound care (10 dogs), via injection (5 dogs), and at time of wound closure (13 dogs) and was used both in open and closed wound management (1 dog). Wounds were associated with SSIs in 18 of 30 sites. Multidrug resistance was noted in 21 of 30 preapplication cultures. Median amikacin dose was 14.5 mg/kg (range, 3 to 59.5 mg/kg), median total volume was 5.0 mL (range, 1 to 12 mL), and median tissue surface area was 6.6 cm2 (range, 1.6 to 36 cm2), for a local wound dose of 62.5 mg/cm2 (range, 6.9 to 214.3 mg/cm2). No short-term adverse local or systemic effects were noted in any wounds or dogs. No dehiscence was seen in 17 of 19 closed sites.
CONCLUSIONS: The results of this case series suggested that Amikacin-P407 can be applied in a variety of ways with no adverse effects. Amikacin-P407 may be considered in open wound management or in a closed setting for infected wounds and SSIs.